About Nagase Medicals Company Overview

Name
Nagase Medicals Co., Ltd.
Capital
498 million yen
Places of Business
Head Office, Itami Plant
Address of Head Office
4-323 Senzo, Itami City, Hyogo Prefecture 664-0898, Japan See on Google Maps
TEL: +81-72-778-7501
FAX: +81-72-778-7506
Business Areas
Development, manufacture, and import/export of ethical drugs, medical devices, medical materials, and veterinary drugs
Date of Establishment
July 1, 1972
Representative
President Mitsuru Akasaka
Number of Employees
Approximately 180
Shareholder
NAGASE & CO., LTD.
Plant
Pharmaceuticals Building: Total building floor area 3893 ㎡
No. 2 Injectables Building : Total building floor area 2538 ㎡
Spray-Dry Building: Total building floor area 1279 ㎡
Quality Control Building: Total building floor area 538 ㎡
Laboratory Building: Total building floor area 625 ㎡
Warehouses (3 buildings): Total building floor area 1420 ㎡
Storage capacity 1700 PL

Access

Head north from the intersection at Senzo 5-chome

Head Office and Itami Plant
4-323 Senzo, Itami City, Hyogo Prefecture 664-0898
TEL: +81-72-778-7501
FAX: +81-72-778-7506

Directions from the closest stations
• 10-minute walk from Hankyu Itami Station
• 10-minute taxi ride from JR Itami Station
• From JR Itami Station, take an Itami City Bus from bus stops 3 or 4 and alight at Senzoguchi, from where it is a 3-minute walk

Directions from a distance
• 15-minute taxi ride from Osaka International Airport (Itami)
• 40-minute taxi ride or local train ride from JR Shin-Osaka Station
• 90-minute bus or taxi ride from Kansai International Airport

Directions by car
• 15 minutes (5 km) from Ikeda Interchange on the Chugoku Expressway
• 15 minutes (5 km) from Amagasaki Interchange on the Meishin Expressway

History

Nagase Medicals Co., Ltd. Teikoku Chemical Industries Co., Ltd.
1938 Company established. Plant construction completed in Itami City, Hyogo Prefecture.
1941 Percamin, a local anesthetic (the first to be made in Japan) launched.
1972 Established as the ethical drugs sales company for Teikoku Chemical Industries. Capitalized at 3 million yen.
1974 Capital increased to 48 million yen.
1979 GMP compliance works completed.
1984 Manufacture and sales of health foods started.
1987 Sales of Lonmiel Capsule, a new anti-ulcer agent, launched. Manufacture of Lonmiel Capsule, a new anti-ulcer agent, started.
1997 Construction of the Pharmaceuticals Building in the Itami Plant completed.
March 2001 Teikoku Chemical Industries transferred its Pharmaceuticals Business Division to Nagase Medicals, which was reorganized as a pharmaceutical manufacturer and its capital increased to 498 million yen.
October 2001 Nagase Medicals transferred its Sales Division for ethical drugs to Merck Hoei Ltd. (now Mylan Seiyaku Ltd.), and was reorganized to specialize in development and manufacturing.
January 2003 Construction of the Injectables Building for manufacturing vials containing highly potent liquid injectables completed.
June 2004 Construction of the Laboratory Building completed.
February 2013 Construction of the No. 2 Injectables Building for manufacturing vials containing highly potent liquid injectables completed.
Latest systems installed, and full-scale development and manufacturing of highly potent injectables, mainly anti-cancer drugs, started.
December 2013 Docetaxel intravenous infusion (anti-cancer drug) launched.
December 2014 Oxaliplatin intravenous infusion (anti-cancer drug) launched.
December 2015 Maxacalcitol intravenous for dialysis (secondary hyperparathyroidism treatment) launched.
December 2017 Construction of building for manufacturing vials containing highly potent lyophilized injectables completed.
Connected to the No. 2 Injectables Building to expand manufacturing capacity for highly potent injectables.